Prof. Manuel Guzman Joins the Scientific Advisory Board of VivaCell Biotechnology

Share Article

Vivacell enhances its network of collaborations in the field of biomedical research on cannabinoids with the addition of Prof. Manuel Guzman to the Scientific Advisory Board of the Company

News Image

VivaCell Biotechnology España has renewed the panel of its Scientific Advisory Board with the addition of Dr. Manuel Guzman Pastor, Professor of Biochemistry and Molecular Biology at Complutense University of Madrid, and current President of the Spanish Society for Research on Cannabinoids (SEIC). Dr. Guzman’s research is focused on the molecular mechanisms that cannabinoids use on the brain and their effect on the regeneration, growth and cell survival in the nervous system. Dr. Guzman publications on cannabinoids and cancer have been recognized as groundbreaking by researchers worldwide and have initiated a long series of new studies in this field. In 2009 he received the award for basic research of the International Association for Cannabinoid Medicines.

Dr. Guzman joins the team of renowned scientists led by Dr. Eduardo Muñoz (Professor of Immunology at University of Córdoba and VivaCell founder), Dr. Javier Fernández Ruiz (Professor of Biochemistry and Molecular Biology at Universidad Complutense of Madrid), Dr. Giovanni Appendino (Professor of Pharmaceutical Chemistry at the Università degli Studi del Piemonte Orientale in Novara Amadeo Avogadro, Italy), and Dr. Bernd Fiebich (Associate Professor, Department of Psychiatry, University of Freiburg, Germany). Additionally, VivaCell is glad to thank Dr. Olov Sterner (Professor of Organic Chemistry at the University of Lund, Switzerland) for his contribution to VivaCell SAB during the Drug Discovery phase of the Company.

With the renewal of its scientific advisory panel, Vivacell enhances its network of collaborations in the field of biomedical research on cannabinoids, and focuses the scientific strategy on the development of its compounds VCE-003 and VCE-004. Both are in preclinical stage for the treatment of neurodegenerative diseases (Huntington's, Parkinson's, Multiple Sclerosis, Amyotrophic Lateral Sclerosis) and fibrotic diseases such as Scleroderma.

About VivaCell Biotechnology España S.L.

VivaCell Biotechnology Spain S.L. was established in 2003 as a spin-off of the AINP (FPV) and Cannabis (FP-VI) EU projects. It was founded by a group of internationally renowned researchers in biomedicine, pharmacology and chemistry of natural products. The founders constitute the Scientific Advisory Board of the company.

In 2012 VivaCell was recognized as a Technology- Based Company of the University of Córdoba (Spain) and enhances its activity with the installation of new laboratories, equipped with the best technology for biomedicine research. In 2012 VivaCell moves to the Technological & Scientific Park of Cordoba. This allows it to face new challenges and maintain a sustainable growth as a biotechnology company.

For more information, please visit http://www.vivacellspain.com or send an email to info(at)vivacellspain(dot)com

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Visit website